Objective: Although hepatitis A virus (HAV) infection is a disease with mild symptoms and good prognosis it may be more severe and even fatal if it develops with a chronic liver disease such as chronic hepatitis B. Therefore, it is important to have information about anti-HAV IgG seroprevalence in patients with chronic hepatitis B. Material and Methods: A total of 156 patients who were diagnosed with chronic hepatitis B infection and who were asked for anti-HAV immunoglobulin G (IgG) test were included in the study. In serum samples, hepatitis B surface antigen (HBsAg) and anti-HAV IgG tests were analyzed using enzyme immunoassay technique. Results: Ages of the patients included in the study ranged from 7 to 88 and 88 (56.4%) of them were male. Anti-HAV IgG seropositivity was detected in 95.5% of the patients. Seropositivity rates were 95.8%, 98%, and 93% in <30, 30-50 and> 50 years old groups, respectively. While anti-HAV IgG positivity was the highest in the age groups of <30 and 30-50 in males with a rate of 100%, it was the highest in the age group of 30-50 in females with a rate of 96.2%. Conclusions: Anti-HAV IgG positivity was detected in 95.5% of the study group and it was concluded that 4.5% of the patients needed vaccination to prevent HAV infection. Investigation of hepatitis A immunization status in patients with other life-threatening chronic liver diseases in addition to chronic hepatitis B virus infection and vaccination of anti-HAV IgG negative patients are recommended.